February 8, 2001
FOR IMMEDIATE RELEASE

CONTACT: Tom Rosenberger, APR, Communications Department (513) 569-5260
CONTACT: Cindy Starr, MSJ, Communications Department (513) 584-2214

The Neuroscience Institute is one of 60 centers across the nation participating in a new clinical trial for the treatment of brain metastases. According to Ronald Warnick, MD, co- principal investigator and neurosurgeon with the Mayfield Clinic and The Neuroscience Institute, this trial will help determine the effects of RSR13 on survival and determine the safety and toxicity of RSR13.

The co-principal investigator is Ashwatha Narayana, MD, Radiation Oncologist. The co- investigators for the study are John Breneman, MD, Radiation Oncologist, and Robert E. Albright, Jr., MD, Neuro-oncologist. The study begins January 1, 2001, and runs through January 1, 2002.

The study is a Phase III randomized, open-label, comparative study of whole brain radiation therapy with or without RSR13 in patients with brain metastases. The purpose of this clinical trial is to evaluate the effects of RSR13, a radioenhancement agent, on metastatic brain tumors. The goal of radioenhancement therapy is to achieve maximal concentrations of oxygen in tumor tissue, decreasing the hypoxic fraction of cells and increasing the radioresponsiveness of solid tumors. RSR13 (administered intravenously immediately before whole brain radiation therapy) enhances the release of oxygen from hemoglobin, enabling more oxygen to be delivered to the hypoxic tissue of solid tumors. Patients who enter the study will be monitored for response to treatment and adverse events.

This study is sponsored by Allos Therapeutics, Inc., and the investigational aspects are provided at no additional cost to the patient.

To inquire about enrollment and eligibility into these clinical trials, call the Mayfield Clinic at 513-558-3179.